Effectiveness and Cost-effectiveness of Levonorgestrel containing Intrauterine system in Primary care against Standard treatment for menorrhagia: a randomised controlled trial

niversity of Birmingham (UK)0 个研究点目标入组 571 人开始时间: 2004年6月11日最近更新: 2023年11月20日

适应症

试验速览

2013 Results article in http://www.ncbi.nlm.nih.gov/pubmed/23301731 results 2015 Results article in http://www.ncbi.nlm.nih.gov/pubmed/26507206 results 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/36376071/ (added 15/11/2022) 2023 Other publications in https://pubmed.ncbi.nlm.nih.gov/37924269/ 10-year observational follow-up study (added 06/11/2023)

•Women between the ages of 25-50 presenting to General Practitioners with menorrhagia, who are not intending to become pregnant in the next 5 years

•1. Taking HRT
•2. Patients with any contraindications to an IUS, with or without Levonorgestrel
•3. Patients with contraindications to medical therapy
•4. Women with abdominally palpable enlarged fibroid uteri (10-12 Weeks size)
•5. Women to whom the contraceptive effect of LNG-IUS would be unacceptable.
•6. Women with symptoms suggestive of other pathology (irregular bleeding, intermenstrual bleeding, postcoital bleeding)
•7. Women with risk factors for endometrial cancer (tamoxifen treatment, unopposed ostrogen treatments)

发起方

niversity of Birmingham (UK)